Annonce

Log ud Log ind
Log ud Log ind
Formue

Bioporto tilbagetrækker USA patentansøgning, genindsender i Q4

Morten W. Langer

søndag 14. juli 2019 kl. 11:05

Fra Bioporto:

BioPorto to redraw U.S. application for regulatory clearance of The NGAL Test™ for risk assessment for AKI in patients under the age of 22 with the intend to resubmit in Q4 2019

July 13, 2019
Announcement no. 14

BioPorto to redraw U.S. application for regulatory clearance of The NGAL Test™ for risk assessment for AKI in patients under the age of 22 with the intend to resubmit in Q4 2019

BioPorto A/S (“BioPorto”) announces today that the company has received an Additional Information (“AI”) request letter from the U.S. Food and Drug Administration (“FDA”) regarding the application for regulatory clearance of the NGAL Test for risk assessment of acute kidney injury (“AKI”) in critical ill patients under the age of 22.

The AI request primarily concerns the clinical study data and collection of retrospective samples, which has been collected in close collaboration with leading kidney specialists at Cincinnati Children’s Hospital in U.S. BioPorto has reviewed FDA’s AI request and concluded, that the existing clinical studies and data do not constitute sufficient basis to proceed with the current application. Therefore, the current application will be redrawn.

BioPorto will now engage in a dialogue with Cincinnati Children’s Hospital and other leading U.S. children hospitals to collect additional retrospective clinical samples. BioPorto will resubmit a new package to FDA during Q4 2019 under the assumption that the clinical sample selection will start in August 2019.

BioPorto and leading kidney specialists in U.S. remain committed to NGAL as an important biomarker for AKI and other indications and will continue discussions with the FDA on potential paths going forward to obtain regulatory clearance of both The NGAL Test for risk assessment of AKI in patients under the age of 22 and the NGAL Test (plasma) for risk assessment of AKI in adults, which is expected to be submitted to FDA later in 2019.

As a consequence of the redraw, BioPorto suspends its financial guidance for 2019 until the publication of the interim report for first half of 2019, which will be published on August 15th 2019.

Tilmeld dig vores gratis nyhedsbrev
ØU Dagens Nyheder Middag - Investering

Vær et skridt foran. Få de vigtigste analyser af danske aktier og aktiemarkedet
Udkommer hver dag kl. 12.

Jeg giver samtykke til, at I sender mig mails med de seneste historier fra Økonomisk Ugebrev. Lejlighedsvis må I gerne sende mig gode tilbud og information om events. Samtidig accepterer jeg ØU’s Privatlivspolitik.

Du kan til enhver tid afmelde dig med et enkelt klik.

[postviewcount]

Jobannoncer

Grønborg: Bankernes rejse nærmer sig afslutningen
Afdelingsdirektør for forretningsudvikling Private Banking
Private Banking
Aabenraa
Grønborg: Bankernes rejse nærmer sig afslutningen
Formuerådgiver
Formuerådgiver
Region hovedstaden og Sjælland
Grønborg: Bankernes rejse nærmer sig afslutningen
Forretningsudvikler til Pension og Formue
Pension, Formue
Aabenraa
Grønborg: Bankernes rejse nærmer sig afslutningen
Formuerådgiver
Formuerådgiver
Midt- og Nordjylland
Generalsekretær i Folkekirkens Nødhjælp
Region Hovedstaden
ØKONOMIMEDARBEJDER – Carlsbergfondet
Region Hovedstaden
Regnskabsassistent til Pharma Nord
Region Syddanmark
Kontorchef for økonomi, analyse og kunder i Færdselsstyrelsen
Region H
DIGITALISERINGSCHEF – Muskelsvindfonden
Region H
Direktionskonsulent med flair for økonomi og udviklingsprojekter
Region Sjælland

Mere fra ØU Formue

Log ind

Har du ikke allerede en bruger? Opret dig her.

Påskegave

Få to GRATIS analyser af Novo Nordisk & Zealand Pharma 

FÅ VORES STORE NYTÅRSUDGAVE AF FORMUE

Her er de 10 bedste aktier i 2022

Tilbuddet udløber om:
dage
timer
min.
sek.

Analyse af og prognoser for Fixed Income (statsrenter og realkreditrenter)

Direkte adgang til opdaterede analyser fra toneangivende finanshuse:

Goldman Sachs

Fidelity

Danske Bank

Morgan Stanley

ABN Amro

Jyske Bank

UBS

SEB

Natixis

Handelsbanken

Merril Lynch 

Direkte adgang til realkreditinstitutternes renteprognoser:

Nykredit

Realkredit Danmark

Nordea

Analyse og prognoser for kort rente, samt for centralbankernes politikker

Links:

RBC

Capital Economics

Yardeni – Central Bank Balance Sheet 

Investing.com: FED Watch Monitor Tool

Nordea

Scotiabank